前列腺素E2对磺脲类药物诱导的胰岛素释放的影响。

Effect of PGE2 on sulfonylurea induced insulin release.

Villar A, Ivorra M D, Anselmi E

Departamento de Farmacognosia y Farmacodinamia, Facultad de Farmacia, Universidad de Valencia, Espagne.

J Physiol (Paris). 1987;82(1):12-7.

Abstract

Previous studies have demonstrated that the administration of prostaglandins (PGs) inhibits insulin secretion in vivo and have suggested that these compounds may be involved in the pathogenesis of diabetes mellitus. The present study was carried out in order to explore the effect of PGE2 on sulfonylurea-induced insulin release. 2. We determined glycemia and insulinemia in rat blood samples, at different times before and after the intraarterial administration of: (a) glibenclamide, (b) tolbutamide, (c) PGE2, (d) glibenclamide and PGE2, (e) tolbutamide and PGE2; in all cases with and without a glucose pulse. (Glibenclamide 0.5 mg/kg, tolbutamide 50 mg/kg, PGE2 100 micrograms/kg and glucose 500 mg/kg). 3. The results of these experiments demonstrate that PGE2 partially inhibits sulfonylurea-induced insulin release. The plasma insulin and glucose levels remain within the range of intermediate values as compared to the control groups (sulfonylurea or PGE2-treated rats) both in presence and absence of glucose.

摘要

先前的研究表明，前列腺素（PGs）的给药在体内会抑制胰岛素分泌，并提示这些化合物可能参与了糖尿病的发病机制。本研究旨在探讨前列腺素E2（PGE2）对磺脲类药物诱导的胰岛素释放的影响。2. 我们在大鼠动脉内给予以下物质之前和之后的不同时间，测定大鼠血液样本中的血糖和胰岛素水平：（a）格列本脲，（b）甲苯磺丁脲，（c）PGE2，（d）格列本脲和PGE2，（e）甲苯磺丁脲和PGE2；所有情况下均有或无葡萄糖脉冲。（格列本脲0.5mg/kg，甲苯磺丁脲50mg/kg，PGE2 100μg/kg，葡萄糖500mg/kg）。3. 这些实验结果表明，PGE2部分抑制磺脲类药物诱导的胰岛素释放。无论有无葡萄糖，与对照组（磺脲类药物或PGE2处理的大鼠）相比，血浆胰岛素和葡萄糖水平均保持在中间值范围内。